- Open Access
Treatment of influenza virus-related critical illness during continuous renal replacement therapy: take caution with dosing
Critical Care volume 24, Article number: 72 (2020)
- The original article was published in Critical Care 2019 23:214
In their discussion, Chow et al. state that for patients who cannot tolerate or absorb enteric oseltamivir due to gastric stasis, malabsorption, or other gastrointestinal processes, intravenous peramivir may be an alternative . They advise a single dose of 600 mg via intravenous infusion, given over 15–30 min . The question that arises is the following: what is the dose to be given during continuous renal replacement therapy (CRRT)? According to the manufacturer’s recommendations, the dose should be adjusted in line with the degree of reduction in creatinine clearance . In a recent case report by Dillon et al., a dose of 200 mg daily, the recommended dose for patients with creatinine clearance of 30–49 mL/min, was given to a patient with acute kidney injury (AKI) managed with CRRT . In practice, as the plasma protein unbound fraction approaches 1 (as is the case with peramivir) and the molecular weight of the drug is low (below 20,000 Da), the sieving coefficient can be estimated to be 1 . As a consequence, in this case report, the dosage scheme (200 mg daily) achieved a smaller serum peak concentration, larger volume of distribution, and a shorter half-life, illustrating the significant differences in pharmacokinetic (PK)/pharmacodynamic (PD) target attainment when drugs are administered in the setting of continuous veno-venous hemodiafiltration (CVVHDF) . Scheetz et al. recommend a steady-state concentration of 17,078 ng/mL, which was averaged from peak and trough concentrations in adult patients with normal renal function . Based on this recommendation, the patient reported by Dillon et al. would have required more than 800 mg given the CRRT settings [2, 4]. Doses of peramivir during CRRT vary from 200 to 800 mg per day in various case reports. This huge difference in dose will have a dramatic influence upon PK/PD during CRRT. Peramivir does not seem to possess any of the classic indications for therapeutic drug monitoring (TDM) (i.e., narrow therapeutic index, high interpatient variability, high intrapatient variability) in patients with normal organ function . However, in patients with critical illness requiring extracorporeal therapies, TDM may provide useful information regarding pharmacokinetic variations and pharmacodynamic target attainment in order to avoid severe underdosing and treatment failure .
Availability of data and materials
Acute kidney injury
Continuous renal replacement therapy
Continuous veno-venous hemodiafiltration
Therapeutic drug monitoring
Chow EJ, Doyle JD, Uyeki TM. Influenza virus-related critical illness: prevention, diagnosis, treatment. Crit Care. 2019;23:214.
Dillon RC, Witcher R, Cies JJ, Moore WS 2nd, Chopra A. Pharmacokinetics of peramivir in an adolescent patient receiving continuous venovenous hemodiafiltration. J Pediatr Pharmacol Ther. 2017;22(1):60–4. https://doi.org/10.5863/1551-6776-22.1.60.
Bohler J, Donauer J, Keller F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int Suppl. 1999;72:S24–8.
Scheetz MH, Griffith MM, Ghossein C, et al. Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous veno-venous hemofiltration. Ann Pharmacother. 2011;45(12):e64.
Winter ME. Basic clinical pharmacokinetics. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 61–7.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Honore, P.M., Kugener, L., Redant, S. et al. Treatment of influenza virus-related critical illness during continuous renal replacement therapy: take caution with dosing. Crit Care 24, 72 (2020). https://doi.org/10.1186/s13054-020-2813-y